SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Annexon Biosciences, a biopharmaceutical company pioneering the development of classical complement pathway inhibitors to treat complement-mediated neurodegenerative diseases (CMND), today announced the appointments of two industry executives to its leadership team. Effective immediately, Mario Saltarelli, M.D., Ph.D., joins as Chief Medical Officer, and Susan Kramer, Dr.P.H., joins as Vice President, Product Development.
